Worst case scenario re: ARBA suit is that PLUS will no longer have the legal costs dragging on earnings. Earnings last Q were $0.26ish, but would have been $0.34ish without legal costsIIRC. Best case of course is to recoup legal costs (probably $1-2 million) plus an award that could easily be dollars per share given low O/S.
PLUS is consistently profitable (their *lowest* EPS from 2000-2004 was $0.80) and is growing both organically and via the Manchester acquisition. IMO this is easily a $20 stock even without the potentially significant win against ARBA.